RecruitingNot applicableNCT05562960
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Studying Primary lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Taiwan University Hospital
- Principal Investigator
- Li-Kai Tsai, MD, PhDNational Taiwan University Hospital
- Intervention
- Plasmapheresis(procedure)
- Enrollment
- 20 target
- Eligibility
- 20 years · All sexes
- Timeline
- 2023 – 2025
Study locations (1)
- National Taiwan University Hospital, Taipei, Taiwan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05562960 on ClinicalTrials.govOther trials for Primary lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07334743Identifying Biomarkers in ALS Patients Using Neuronal Derived Extracellular VesiclesFondation Ophtalmologique Adolphe de Rothschild
- RECRUITINGNANCT07491562Evaluation of a Structurally Suitable Neck Exoskeleton in Patients With Amyotrophic Lateral SclerosisUniversity of Utah
- RECRUITINGNCT06318585Creation of a Clinical Database for the Study of Phenotypic Variability in Motor Neuron DiseasesIstituto Auxologico Italiano
- ACTIVE NOT RECRUITINGPHASE1NCT02868567Use of Dalfampridine in Primary Lateral SclerosisHospital for Special Surgery, New York
- RECRUITINGNCT02567136Imaging Biomarkers in ALSUniversity of Minnesota